[go: up one dir, main page]

TW202509022A - Method of preparing intermediates for synthesizing xanthine oxidase inhibitor - Google Patents

Method of preparing intermediates for synthesizing xanthine oxidase inhibitor Download PDF

Info

Publication number
TW202509022A
TW202509022A TW113125897A TW113125897A TW202509022A TW 202509022 A TW202509022 A TW 202509022A TW 113125897 A TW113125897 A TW 113125897A TW 113125897 A TW113125897 A TW 113125897A TW 202509022 A TW202509022 A TW 202509022A
Authority
TW
Taiwan
Prior art keywords
chemical formula
preparation
hydrogen
added
alkyl
Prior art date
Application number
TW113125897A
Other languages
Chinese (zh)
Inventor
鄭喜樂
朴雅別
金琪大
徐正珉
李錫柱
李主悅
Original Assignee
南韓商Lg化學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Lg化學股份有限公司 filed Critical 南韓商Lg化學股份有限公司
Publication of TW202509022A publication Critical patent/TW202509022A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure relates to a method of preparing an intermediate for a synthesis of a xanthine oxidase inhibitor, and more specifically, to a method of efficiently preparing a compound of the following Chemical Formula 3 through a work-up process using ammonia water and citric acid: In the above Chemical Formula 3, R1, R2, R3, R4, and R5 are as defined in the specification.

Description

製備用於合成黃嘌呤氧化酶抑制劑之中間體之方法Method for preparing intermediates for synthesizing xanthine oxidase inhibitors

本揭露有關一種製備用於合成黃嘌呤氧化酶抑制劑之中間體之方法,更具體地,有關一種通過使用氨水和檸檬酸之後處理(work-up)程序有效率地製備以下化學式3之化合物之方法:The present disclosure relates to a method for preparing an intermediate for synthesizing a xanthine oxidase inhibitor, and more particularly, to a method for efficiently preparing a compound of the following chemical formula 3 by a work-up procedure using aqueous ammonia and citric acid:

[化學式3][Chemical formula 3]

在以上化學式3中,R1、R2、R3、R4以及R5係如本文中所定義。In the above Chemical Formula 3, R1, R2, R3, R4 and R5 are as defined herein.

已知黃嘌呤氧化酶(Xanthine oxidase)是將次黃嘌呤轉化成黃嘌呤,並且將形成之黃嘌呤轉化成尿酸的酵素。尿酸酶存在於大多數哺乳動物中,但不存在於人類和黑猩猩中,因此已知尿酸是嘌呤代謝的最終產物(SP Bruce, Ann. Pharm., 2006, 40, 2187~2194)。血液中維持高濃度的尿酸會造成多種疾病,並且其代表性實例為痛風。Xanthine oxidase is an enzyme that converts hypoxanthine into xanthine and converts the resulting xanthine into uric acid. Uricase is present in most mammals, but not in humans and chimpanzees, so uric acid is known to be the final product of purine metabolism (SP Bruce, Ann. Pharm., 2006, 40, 2187~2194). High concentrations of uric acid in the blood can cause a variety of diseases, and a representative example is gout.

如以上所述,痛風是一種由體內高濃度尿酸造成的疾病,並且是指尿酸結晶積累在關節軟骨、韌帶以及周圍組織中並誘發嚴重發炎和疼痛之病況。痛風是一種發炎性關節疾病,近40年來發病率已穩定上升(N.L. Edwards, Arthritis & Rheumatism, 2008, 58, 2587~2590)。As mentioned above, gout is a disease caused by high concentrations of uric acid in the body, and refers to a condition in which uric acid crystals accumulate in joint cartilage, ligaments, and surrounding tissues, causing severe inflammation and pain. Gout is an inflammatory joint disease, and its incidence has been steadily increasing over the past 40 years (N.L. Edwards, Arthritis & Rheumatism, 2008, 58, 2587~2590).

據此,業經進行各種研究以開發新型黃嘌呤氧化酶抑制劑,並且韓國專利公開號10-2011-0037883揭示一種有效作為黃嘌呤氧化酶抑制劑之以下化學式之新穎化合物:Accordingly, various studies have been conducted to develop novel xanthine oxidase inhibitors, and Korean Patent Publication No. 10-2011-0037883 discloses a novel compound of the following chemical formula effective as a xanthine oxidase inhibitor:

在韓國公開專利公開號10-2011-0037883中,描述5-溴-3-氰基-1-異丙基-吲哚的傳統製備步驟,5-溴-3-氰基-1-異丙基-吲哚是黃嘌呤氧化酶抑制劑CsCO 3之中間體,其係由於經濟效率低而不方便使用且高使用密度,因此需要尋找替代品。此外,由於沒有確定之純化方法,將反應和後處理(work-up)程序後獲得之有機層濃縮並立即進行下一個反應。在這種情況下,出現由於未純化而含在反應混合物中的5-溴-3-氰基-1H-吲哚或為引發作用劑(causative agent)而在下一個反應中產生雜質且不利地影響產品品質之問題。 In Korean Patent Publication No. 10-2011-0037883, a conventional preparation process of 5-bromo-3-cyano-1-isopropyl-indole is described. 5-bromo-3-cyano-1-isopropyl-indole is an intermediate of the xanthine oxidase inhibitor CsCO 3 , which is inconvenient to use due to its low economic efficiency and high usage density, and therefore a substitute is needed. In addition, since there is no established purification method, the organic layer obtained after the reaction and work-up process is concentrated and immediately subjected to the next reaction. In this case, there arises a problem that 5-bromo-3-cyano-1H-indole contained in the reaction mixture without being purified or as a causative agent generates impurities in the next reaction and adversely affects the quality of the product.

此外,傳統的1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯之製備步驟具有35至48小時之非常長的反應時間,並且殘留起始材料5-溴-3-氰基-1-異丙基-吲哚且產生各種雜質,導致影響原料藥品,因此需要在品質和產率方面改善。Furthermore, the conventional preparation process of 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester has a very long reaction time of 35 to 48 hours, and the starting material 5-bromo-3-cyano-1-isopropyl-indole remains and various impurities are generated, resulting in an influence on the raw material drug, and thus improvement in quality and yield is required.

針對以上問題,韓國專利公開號10-2023-0006408揭示一種使用低成本起始材料和配體之製備方法,以及螯合萃取純化技術。To address the above issues, Korean Patent Publication No. 10-2023-0006408 discloses a preparation method using low-cost starting materials and ligands, as well as a chelating extraction purification technology.

在以上製備方法中,在1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯反應完成後之後處理程序揭示於以下示意圖。 反應IPC 第1次後處理 10%檸檬酸,6N HCl (pH 2至3) 層分離(水層棄置) 第2次後處理 5% EDTA二鈉 層分離(水層棄置) 第3次後處理 5% EDTA二鈉 層分離(水層棄置) 第4次後處理 H 2O 層分離(水層棄置) 蒸發 In the above preparation method, the post-treatment process after the reaction of 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester is completed is disclosed in the following schematic diagram. Respond to IPC First post-processing 10% citric acid, 6N HCl (pH 2 to 3) Layer separation (water layer discard) Second post-processing 5% Disodium EDTA Layer separation (water layer discard) 3rd post-processing 5% Disodium EDTA Layer separation (water layer discard) 4th post-processing H2O Layer separation (water layer discard) Evaporation

在以上製備方法中,雖然使用用於C-N偶聯反應的銅催化劑檸檬酸和螯合劑(諸如,EDTA)並以HCl調節pH,但是出於導入後處理的目的之Cu移除率不穩定且重複數個後處理步驟,因此製程效率低,並且有在注入HCl期間突然產生大量二氧化碳的問題,可能存在安全性風險。 先前技術 專利文件 In the above preparation method, although the copper catalyst citric acid and chelating agent (e.g., EDTA) for CN coupling reaction are used and the pH is adjusted with HCl, the Cu removal rate for the purpose of post-treatment is unstable and several post-treatment steps are repeated, so the process efficiency is low, and there is a problem of sudden generation of a large amount of carbon dioxide during the injection of HCl, which may pose a safety risk. Prior Art Patent Documents

韓國專利申請案早期公開號10-2011-0037883Korean Patent Application Early Publication No. 10-2011-0037883

韓國專利申請案早期公開號10-2023-0006408Korean Patent Application Early Publication No. 10-2023-0006408

技術問題Technical issues

因此,本揭露之技術主題提供一種改善之新穎製備方法,其能夠可再現地純化銅催化劑,以及在無pH控制下最小化後處理重複次數以製備以下化學式3之化合物,該化合物為合成黃嘌呤氧化酶抑制劑之關鍵中間體:Therefore, the technical subject of the present disclosure provides an improved novel preparation method, which can reproducibly purify the copper catalyst and minimize the number of post-treatment repetitions without pH control to prepare the compound of the following chemical formula 3, which is a key intermediate for the synthesis of xanthine oxidase inhibitors:

[化學式3][Chemical formula 3]

在以上化學式3中,R1、R2、R3、R4以及R5係如本文中所定義。 技術方案 In the above chemical formula 3, R1, R2, R3, R4 and R5 are as defined herein.

達成以上目的之本揭露之態樣提供一種以下化學式3之化合物之製備方法,該製備方法包括:The present disclosure in order to achieve the above object provides a method for preparing a compound of the following chemical formula 3, the method comprising:

在有機溶劑中,以銅催化劑、鹼以及配體進行化學式1之化合物與化學式2之化合物之C-N偶聯反應;以及In an organic solvent, a copper catalyst, a base and a ligand are used to carry out a C-N coupling reaction of the compound of Chemical Formula 1 and the compound of Chemical Formula 2; and

使用10至20 wt.%的氨水NH 4OH或10至20 wt.%的氯化銨(NH 4Cl)水溶液和檸檬酸純化化學式3之化合物: The compound of Formula 3 is purified using 10 to 20 wt.% aqueous ammonia (NH 4 OH) or 10 to 20 wt.% aqueous ammonium chloride (NH 4 Cl) and citric acid:

[化學式1][Chemical formula 1]

[化學式2][Chemical formula 2]

[化學式3][Chemical formula 3]

在以上化學式中,In the above chemical formula,

X為F、Cl、Br或I;X is F, Cl, Br or I;

R1為氫或CN;R1 is hydrogen or CN;

R2為氫、鹵素、C 1-C 7烷基、C 1-C 7烷氧基-C 1-C 7烷基或苯基; R2 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl or phenyl;

R3為氫;未經取代或經一或多個選自鹵素、C 3-C 7環烷基以及O-R6之取代基取代之C 1-C 7烷基;C 3-C 7環烷基;或 , 其中R6表示C 1-C 4烷基,W表示O或S,R7表示氫或C 1-C 4烷基,以及n為0至3之整數; R3 is hydrogen; C 1 -C 7 alkyl which is unsubstituted or substituted with one or more substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or , wherein R6 represents a C 1 -C 4 alkyl group, W represents O or S, R7 represents hydrogen or a C 1 -C 4 alkyl group, and n is an integer from 0 to 3;

R4為氫、鹵素或C 1-C 7烷基;以及 R4 is hydrogen, halogen or C 1 -C 7 alkyl; and

R5為-C(O)OR8,其中R8為氫、C 1-C 7烷基或C 3-C 7環烷基。 本發明之功效 R5 is -C( O )OR8, wherein R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl.

根據本揭露之製備方法,製備之化學式3之化合物中之銅催化劑的殘留量可再現地保持在小於50 ppm。根據本揭露之製備方法,藉由將後處理程序的重複次數減少至三次,而減少製程時間和產生之廢液的量,從而提高製備效率。此外,根據本揭露之製備方法,可藉由省略pH控制步驟並阻斷二氧化碳的快速產生而提高製程安全性。 最佳模式 According to the preparation method disclosed herein, the residual amount of the copper catalyst in the prepared compound of Chemical Formula 3 can be reproducibly maintained at less than 50 ppm. According to the preparation method disclosed herein, by reducing the number of repetitions of the post-treatment procedure to three times, the process time and the amount of waste liquid generated are reduced, thereby improving the preparation efficiency. In addition, according to the preparation method disclosed herein, the process safety can be improved by omitting the pH control step and blocking the rapid generation of carbon dioxide. Best Mode

後文中,將更詳細地描述本揭露。In the following text, the present disclosure will be described in more detail.

根據本揭露之具體實例,配體可選自N,N-二甲基乙二胺、四甲基乙二胺、1,2-環己二胺、N,N’-二甲基-1,2-環己二胺、1,10-啡啉以及脯胺酸所組成群組,但不限於此。根據本發明之具體實例,配體可為N,N-二甲基乙胺。以化學式1之化合物之重量為基準計,使用之配體的量可為0.2至1.0當量,或較佳為0.4當量。According to the specific examples of the present disclosure, the ligand can be selected from the group consisting of N,N-dimethylethylenediamine, tetramethylethylenediamine, 1,2-cyclohexanediamine, N,N'-dimethyl-1,2-cyclohexanediamine, 1,10-phenanthroline and proline, but is not limited thereto. According to the specific examples of the present invention, the ligand can be N,N-dimethylethylamine. The amount of the ligand used can be 0.2 to 1.0 equivalents, or preferably 0.4 equivalents, based on the weight of the compound of Chemical Formula 1.

根據本揭露之具體實例,有機溶劑可選自由甲苯、二甲苯、二甲基甲醯胺(DMF)、二甲亞碸(DMSO)及其混合物所組成群組,但不限於此。根據本發明之具體實例,有機溶劑可為甲苯。以化學式1之化合物之重量為基準計,使用之有機溶劑的量可為4倍(ml/g)至8倍(ml/g),較佳為4倍(ml/g)至6倍(ml/g)。According to the specific examples of the present disclosure, the organic solvent can be selected from the group consisting of toluene, xylene, dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and mixtures thereof, but is not limited thereto. According to the specific examples of the present invention, the organic solvent can be toluene. Based on the weight of the compound of Chemical Formula 1, the amount of the organic solvent used can be 4 times (ml/g) to 8 times (ml/g), preferably 4 times (ml/g) to 6 times (ml/g).

根據本發明之具體實例,銅催化劑可選自由碘化銅(I)(CuI)、乙酸銅(II)(Cu(OAc) 2)、銅(Cu)、氧化銅(I)(Cu 2O)、氧化銅(II)(CuO)及其混合物所組成群組,但不限於此。根據本發明之具體實例,銅催化劑可為CuI。以化學式1之化合物之重量為基準計,使用之銅催化劑的量可為0.1當量至0.5當量,較佳為0.1當量至0.3當量,或更佳為0.2當量。 According to a specific embodiment of the present invention, the copper catalyst can be selected from the group consisting of copper (I) iodide (CuI), copper (II) acetate (Cu(OAc) 2 ), copper (Cu), copper (I) oxide (Cu 2 O), copper (II) oxide (CuO) and mixtures thereof, but is not limited thereto. According to a specific embodiment of the present invention, the copper catalyst can be CuI. Based on the weight of the compound of Chemical Formula 1, the amount of the copper catalyst used can be 0.1 equivalent to 0.5 equivalent, preferably 0.1 equivalent to 0.3 equivalent, or more preferably 0.2 equivalent.

根據本發明之具體實例,鹼可選自由碳酸鉀(K 2CO 3)、碳酸銫(Cs 2CO 3)、磷酸三鉀(K 3PO 4)、三乙胺、三級丁醇鈉及其混合物所組成群組,但不限於此。根據本發明之具體實例,鹼可為碳酸鉀。以化學式1之化合物之重量為基準計,使用之鹼的量可為1當量至4當量,較佳為1當量至3當量,或更佳為2當量。 According to a specific embodiment of the present invention, the base can be selected from the group consisting of potassium carbonate (K 2 CO 3 ), cesium carbonate (Cs 2 CO 3 ), tripotassium phosphate (K 3 PO 4 ), triethylamine, sodium tertiary butoxide and a mixture thereof, but is not limited thereto. According to a specific embodiment of the present invention, the base can be potassium carbonate. Based on the weight of the compound of Chemical Formula 1, the amount of the base used can be 1 to 4 equivalents, preferably 1 to 3 equivalents, or more preferably 2 equivalents.

根據本揭露之具體實例,可使用12至16 wt.%的氨水NH 4OH。根據本發明之具體實例,可使用15 wt.%的氨水NH 4OH。根據本發明之具體實例,可使用10至20 wt.%的氯化銨(NH 4Cl)。 According to a specific example of the present disclosure, 12 to 16 wt.% of aqueous ammonia (NH 4 OH) may be used. According to a specific example of the present invention, 15 wt.% of aqueous ammonia (NH 4 OH) may be used. According to a specific example of the present invention, 10 to 20 wt.% of ammonium chloride (NH 4 Cl) may be used.

根據本揭露之具體實例,可使用5至15 wt.%的檸檬酸。根據本發明之具體實例,可使用7至12 wt.%的檸檬酸。根據本發明之具體實例,可使用10 wt.%的檸檬酸。According to a specific embodiment of the present disclosure, 5 to 15 wt.% of citric acid can be used. According to a specific embodiment of the present invention, 7 to 12 wt.% of citric acid can be used. According to a specific embodiment of the present invention, 10 wt.% of citric acid can be used.

根據本揭露之具體實例,可進一步包括使用淨化水純化化學式3之化合物之步驟。According to the specific example of the present disclosure, the step of purifying the compound of Chemical Formula 3 using purified water may be further included.

根據本揭露之具體實例,在以上化學式中,X可為Br,Rl可為CN,R2可為氫,R3可為異丙基,R4可為氫,以及R5可為乙氧基羰基(-C(O)OEt)。According to specific embodiments of the present disclosure, in the above chemical formula, X may be Br, R1 may be CN, R2 may be hydrogen, R3 may be isopropyl, R4 may be hydrogen, and R5 may be ethoxycarbonyl (—C(O)OEt).

根據本揭露之具體實例,不同於相關技術領域中之移除效率具有較大偏差,製備之化學式3之化合物中之銅催化劑的殘留量可穩定保持在小於50 ppm,因此是可再現的。更具體地,當使用氨水NH 4OH時,殘留量可穩定保持在小於1 ppm,或當使用氯化銨(NH 4Cl)水溶液時,殘留量可穩定保持在小於50 ppm。 According to the specific examples of the present disclosure, unlike the removal efficiency in the related art with a large deviation, the residual amount of the copper catalyst in the prepared compound of Chemical Formula 3 can be stably maintained at less than 50 ppm, and is therefore reproducible. More specifically, when using ammonia NH 4 OH, the residual amount can be stably maintained at less than 1 ppm, or when using an aqueous solution of ammonium chloride (NH 4 Cl), the residual amount can be stably maintained at less than 50 ppm.

根據本發明之具體實例,減少製備方法中產生的廢液的量和阻斷二氧化碳的快速產生,從而提高製程的穩定性。According to a specific example of the present invention, the amount of waste liquid generated in the preparation method is reduced and the rapid generation of carbon dioxide is blocked, thereby improving the stability of the process.

後文中,將通過實施例更詳細地描述本揭露。然而,下列實施例僅為闡釋性的以利於理解本揭露,本揭露之範疇不限於此。 實施例 1 Hereinafter, the present disclosure will be described in more detail through embodiments. However, the following embodiments are merely illustrative to facilitate understanding of the present disclosure, and the scope of the present disclosure is not limited thereto.

添加5-溴-3-氰基-1-異丙基-吲哚(100.0 g)、1H-吡唑-4-甲酸乙酯(58.6 g)、K 2CO 3(105.1 g)以及甲苯(400 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(14.5 g)和N,N-二甲基乙二胺(DMEDA)(13.4 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加15 wt.%氨水NH 4OH(400 ml)和乙酸乙酯(EtOAc)(400 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(400 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(400 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(500 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(400 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (100.0 g), ethyl 1H-pyrazole-4-carboxylate (58.6 g), K 2 CO 3 (105.1 g) and toluene (400 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (14.5 g) and N,N-dimethylethylenediamine (DMEDA) (13.4 g) were further added, heated, and purged with N 2 until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., 15 wt.% aqueous ammonia NH 4 OH (400 ml) and ethyl acetate (EtOAc) (400 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (400 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (400 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (500 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (400 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實施例 2 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Example 2

添加5-溴-3-氰基-1-異丙基-吲哚(400.0 g)、1H-吡唑-4-甲酸乙酯(234.3 g)、K 2CO 3(420.2 g)以及甲苯(1,600 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(57.9 g)和N,N-二甲基乙二胺(DMEDA)(53.6 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加15 wt.%氨水NH 4OH(1,600 ml)和乙酸乙酯(EtOAc)(1,600 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(1,600 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(1,600 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(2,000 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(1,600 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (400.0 g), ethyl 1H-pyrazole-4-carboxylate (234.3 g), K 2 CO 3 (420.2 g) and toluene (1,600 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (57.9 g) and N,N-dimethylethylenediamine (DMEDA) (53.6 g) were added, heated, and purged with N 2 until the internal temperature reached 45 to 50°C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40°C, 15 wt.% aqueous ammonia NH 4 OH (1,600 ml) and ethyl acetate (EtOAc) (1,600 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (1,600 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (1,600 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (2,000 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (1,600 ml) and dried to give 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實施例 3 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Example 3

添加5-溴-3-氰基-1-異丙基-吲哚(1,600.0 g)、1H-吡唑-4-甲酸乙酯(937.3 g)、K 2CO 3(1,680.8 g)以及甲苯(6,400 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(231.6 g)和N,N-二甲基乙二胺(DMEDA)(214.4 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加15 wt.%氨水NH 4OH(6,400 ml)和乙酸乙酯(EtOAc) (6,400 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(6,400 ml)後,攪拌混合物並靜置各30 分鐘以移除水層。最後,添加淨化水(6,400 ml),攪拌並靜置30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(8,000 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(6,400 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (1,600.0 g), ethyl 1H-pyrazole-4-carboxylate (937.3 g), K 2 CO 3 (1,680.8 g) and toluene (6,400 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (231.6 g) and N,N-dimethylethylenediamine (DMEDA) (214.4 g) were added, heated, and purged with N 2 until the internal temperature reached 45 to 50°C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40°C, 15 wt.% aqueous ammonia NH 4 OH (6,400 ml) and ethyl acetate (EtOAc) (6,400 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (6,400 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (6,400 ml) was added, stirred and allowed to stand for 30 minutes to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (8,000 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (6,400 ml) and dried to give 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實施例 4 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Example 4

添加比較例1-2中所得之1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸乙酯(Cu含量:50000 ppm/50 g)、甲苯(175ml)、EtOAc(175ml)以及15 wt.%氨水(175ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(175 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(175 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加IPA(220 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(175 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester (Cu content: 50000 ppm/50 g) obtained in Comparative Example 1-2, toluene (175 ml), EtOAc (175 ml) and 15 wt.% aqueous ammonia (175 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (175 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (175 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, IPA (220 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (175 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實施例 5 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Example 5

添加實施例4中所得之1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯(Cu含量:小於1 ppm/40 g)、甲苯(140 ml)、EtOAc(140 ml)以及15 wt.%氨水(140 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(140 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(140 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加IPA(176 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(140 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester (Cu content: less than 1 ppm/40 g) obtained in Example 4, toluene (140 ml), EtOAc (140 ml) and 15 wt.% aqueous ammonia (140 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (140 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (140 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, IPA (176 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (140 ml) and dried to give 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實施例 6 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Example 6

添加5-溴-3-氰基-1-異丙基-吲哚(1,600.0 g)、1H-吡唑-4-甲酸乙酯(937.3 g)、K 2CO 3(1,680.8 g)以及甲苯(6,400 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(231.6 g)和N,N-二甲基乙二胺(DMEDA)(214.4 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加10 wt.%氯化銨(NH 4Cl)(6,400 ml)和乙酸乙酯(EtOAc) (6,400 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(6,400 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(6,400 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(8,000 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(6,400 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (1,600.0 g), ethyl 1H-pyrazole-4-carboxylate (937.3 g), K 2 CO 3 (1,680.8 g) and toluene (6,400 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (231.6 g) and N,N-dimethylethylenediamine (DMEDA) (214.4 g) were added, heated, and purged with N 2 until the internal temperature reached 45 to 50°C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40°C, 10 wt.% ammonium chloride (NH 4 Cl) (6,400 ml) and ethyl acetate (EtOAc) (6,400 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (6,400 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (6,400 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (8,000 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (6,400 ml) and dried to give 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 比較例 1-1 1-7 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Comparative Examples 1-1 to 1-7

添加5-溴-3-氰基-1-異丙基-吲哚(220 kg)、1H-吡唑-4-甲酸乙酯(129 kg)、K 2CO 3(231 kg)以及甲苯(880 L),攪拌,以及N 2吹掃約30分鐘。另外添加CuI(32 kg)和DMEDA(30 kg),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加10 wt.%檸檬酸(880 L)和EtOAc(880 L),以及接著緩慢地添加6N HCl直到pH=2至3。添加完成後,攪拌混合物並靜置各30分鐘,以及接著移除水層。添加5 wt.%EDTA(880 L)後,將藉由攪拌並靜置各30分鐘而移除水層之程序各進行兩次。最後,添加淨化水(880 L)後,藉由攪拌和靜置各30分鐘而移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA) (880L),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(880 L)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。重複相同程序7次以確認再現性。 5-Bromo-3-cyano-1-isopropyl-indole (220 kg), ethyl 1H-pyrazole-4-carboxylate (129 kg), K 2 CO 3 (231 kg), and toluene (880 L) were added, stirred, and N 2 purged for about 30 minutes. CuI (32 kg) and DMEDA (30 kg) were further added, heated, and N 2 purged was continued until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., 10 wt.% citric acid (880 L) and EtOAc (880 L) were added, and then 6N HCl was slowly added until pH = 2 to 3. After the addition was completed, the mixture was stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 5 wt.% EDTA (880 L), the process of removing the aqueous layer by stirring and standing for 30 minutes each was repeated twice. Finally, after adding purified water (880 L), the aqueous layer was removed by stirring and standing for 30 minutes each. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (880 L) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (880 L) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester. The same procedure was repeated 7 times to confirm reproducibility.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 比較例 2 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Comparative Example 2

添加5-溴-3-氰基-1-異丙基-吲哚(20.0 g)、1H-吡唑-4-甲酸乙酯(11.7 g)、K 2CO 3(21.0 g)以及甲苯(80 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(2.9 g)和DMEDA(2.68 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加10 wt.%檸檬酸(80 ml)和EtOAc (80 ml),以及接著緩慢地添加6N HCl直到pH=2至3。添加完成後,攪拌混合物並靜置各30分鐘,以及接著移除水層。添加5 wt.%EDTA(80 ml)後,將藉由攪拌並靜置各30分鐘而移除水層之程序進行兩次。最後,添加淨化水(80 ml)後,藉由攪拌和靜置各30分鐘而移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(80 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(80 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (20.0 g), ethyl 1H-pyrazole-4-carboxylate (11.7 g), K 2 CO 3 (21.0 g) and toluene (80 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (2.9 g) and DMEDA (2.68 g) were further added, heated, and purged with N 2 until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., 10 wt.% citric acid (80 ml) and EtOAc (80 ml) were added, and then 6N HCl was slowly added until pH = 2 to 3. After the addition was completed, the mixture was stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 5 wt.% EDTA (80 ml), the procedure of removing the aqueous layer by stirring and standing for 30 minutes each was repeated twice. Finally, after adding purified water (80 ml), the aqueous layer was removed by stirring and standing for 30 minutes each. After the organic layer thus obtained was distilled as much as possible, isopropyl alcohol (IPA) (80 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (80 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 比較例 3-1 3-2 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Comparison of Examples 3-1 and 3-2

添加5-溴-3-氰基-1-異丙基-吲哚(20.0 g)、1H-吡唑-4-甲酸乙酯(11.7 g)、K 2CO 3(21.0 g)以及甲苯(80 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(2.9 g)和DMEDA(2.68 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,並且添加10 wt.%檸檬酸(80 ml)和EtOAc(80 ml),以及接著緩慢地添加6N HCl直到pH=2至3。添加完成後,攪拌混合物並靜置各30分鐘,以及接著移除水層。添加5 wt.%氨水(80 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(80 ml)後,攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(80 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(80 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。重複相同程序兩次以確認再現性。 5-Bromo-3-cyano-1-isopropyl-indole (20.0 g), ethyl 1H-pyrazole-4-carboxylate (11.7 g), K 2 CO 3 (21.0 g) and toluene (80 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (2.9 g) and DMEDA (2.68 g) were further added, heated, and purged with N 2 until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., and 10 wt.% citric acid (80 ml) and EtOAc (80 ml) were added, and then 6N HCl was slowly added until pH = 2 to 3. After the addition was completed, the mixture was stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 5 wt.% aqueous ammonia (80 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, after adding purified water (80 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After the organic layer thus obtained was distilled as much as possible, isopropyl alcohol (IPA) (80 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (80 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester. The same procedure was repeated twice to confirm reproducibility.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 比較例 4-1 4-2 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Comparative Examples 4-1 and 4-2

添加5-溴-3-氰基-1-異丙基-吲哚(20.0 g)、1H-吡唑-4-甲酸乙酯(11.7 g)、K 2CO 3(21.0 g)以及甲苯(80 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(2.9 g)和DMEDA(2.68 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加5 wt.%氨水(80 ml)和EtOAc(80 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加10 wt.%檸檬酸(80 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(80 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(80 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(80 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。重複相同程序兩次以確認再現性。 5-Bromo-3-cyano-1-isopropyl-indole (20.0 g), ethyl 1H-pyrazole-4-carboxylate (11.7 g), K 2 CO 3 (21.0 g) and toluene (80 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (2.9 g) and DMEDA (2.68 g) were further added, heated, and purged with N 2 until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., 5 wt.% aqueous ammonia (80 ml) and EtOAc (80 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 10 wt.% citric acid (80 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (80 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (80 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (80 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester. The same procedure was repeated twice to confirm reproducibility.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 比較例 5 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Comparative Example 5

添加5-溴-3-氰基-1-異丙基-吲哚(20.0 g)、1H-吡唑-4-甲酸乙酯(11.7 g)、K 2CO 3(21.0 g)以及甲苯(80 ml),攪拌,以及以N 2吹掃約30分鐘。另外添加CuI(2.9 g)和DMEDA(2.68 g),加熱,及繼續以N 2吹掃,直到內部溫度達到45至50℃。確認反應在回流條件下完成後,將混合物冷卻至30至40℃,添加5 wt.%氨水(110 ml)和EtOAc(80 ml),攪拌並靜置各30分鐘,以及接著移除水層。添加5 wt.%氨水(80 ml)後,攪拌混合物並靜置各30分鐘以移除水層。最後,添加淨化水(80 ml),攪拌並靜置各30分鐘以移除水層。將如此得到之有機層盡可能蒸餾後,添加異丙醇(IPA)(80 ml),加熱以完全溶解,以及接著緩慢地冷卻以再結晶。過濾所得之固體,以及接著以IPA(80 ml)洗滌並乾燥以得到1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯。 5-Bromo-3-cyano-1-isopropyl-indole (20.0 g), ethyl 1H-pyrazole-4-carboxylate (11.7 g), K 2 CO 3 (21.0 g) and toluene (80 ml) were added, stirred, and purged with N 2 for about 30 minutes. CuI (2.9 g) and DMEDA (2.68 g) were further added, heated, and purged with N 2 until the internal temperature reached 45 to 50° C. After confirming that the reaction was completed under reflux conditions, the mixture was cooled to 30 to 40° C., 5 wt.% aqueous ammonia (110 ml) and EtOAc (80 ml) were added, stirred and allowed to stand for 30 minutes each, and then the aqueous layer was removed. After adding 5 wt.% aqueous ammonia (80 ml), the mixture was stirred and allowed to stand for 30 minutes each to remove the aqueous layer. Finally, purified water (80 ml) was added, stirred and allowed to stand for 30 minutes each to remove the aqueous layer. After distilling the organic layer thus obtained as much as possible, isopropyl alcohol (IPA) (80 ml) was added, heated to completely dissolve, and then slowly cooled to recrystallize. The obtained solid was filtered, and then washed with IPA (80 ml) and dried to obtain 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester.

1H-NMR (CDCl 3) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) 實驗例 1 H-NMR (CDCl 3 ) δ 8.45 (1H, s), 8.13 (1H, s), 8.03 (1H, d), 7.80 (1H, s), 7.75 (1H, dd), 7.54 (1H, d), 4.79-4.69 (1H, m), 4.36 (2H, q), 1.61 (6H, d), 1.40 (3H, t) Experimental Example

測量實施例和比較例所製備之1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸乙酯中之殘留的Cu含量,並於表1中顯示。The residual Cu content in the 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid ethyl ester prepared in the Examples and Comparative Examples was measured and shown in Table 1.

Claims (11)

一種以下化學式3之化合物之製備方法,其包含: 在有機溶劑中,以銅催化劑、鹼以及含有N,N-二甲基乙二胺之配體進行化學式1之化合物與化學式2之化合物之C-N偶聯反應;以及 使用10至20 wt.%的氨水NH 4OH或10至20 wt.%的氯化銨(NH 4Cl)水溶液和檸檬酸純化化學式3之化合物: [化學式1] [化學式2] [化學式3] 在以上化學式中, X為F、Cl、Br或I, R1為氫或CN, R2為氫、鹵素、C 1-C 7烷基、C 1-C 7烷氧基-C 1-C 7烷基、或苯基, R3為氫,未經取代或經一或多個選自鹵素、C 3-C 7環烷基以及O-R6之取代基取代之C 1-C 7烷基;C 3-C 7環烷基;或 ,其中R6表示C 1-C 4烷基,W表示O或S,R7表示氫或C 1-C 4烷基,以及n為0至3的整數, R4為氫、鹵素或C 1-C 7烷基,以及 R5為-C(O)OR8,其中R8為氫、C 1-C 7烷基或C 3-C 7環烷基。 A method for preparing a compound of the following chemical formula 3 comprises: performing a CN coupling reaction of a compound of the chemical formula 1 and a compound of the chemical formula 2 using a copper catalyst, a base and a ligand containing N,N-dimethylethylenediamine in an organic solvent; and purifying the compound of the chemical formula 3 using 10 to 20 wt.% ammonia NH 4 OH or 10 to 20 wt.% ammonium chloride (NH 4 Cl) aqueous solution and citric acid: [Chemical Formula 1] [Chemical formula 2] [Chemical formula 3] In the above chemical formula, X is F, Cl, Br or I, R1 is hydrogen or CN, R2 is hydrogen, halogen, C 1 -C 7 alkyl, C 1 -C 7 alkoxy-C 1 -C 7 alkyl, or phenyl, R3 is hydrogen, C 1 -C 7 alkyl which is unsubstituted or substituted with one or more substituents selected from halogen, C 3 -C 7 cycloalkyl and O-R6; C 3 -C 7 cycloalkyl; or , wherein R6 represents C 1 -C 4 alkyl, W represents O or S, R7 represents hydrogen or C 1 -C 4 alkyl, and n is an integer from 0 to 3, R4 is hydrogen, halogen or C 1 -C 7 alkyl, and R5 is -C(O)OR8, wherein R8 is hydrogen, C 1 -C 7 alkyl or C 3 -C 7 cycloalkyl. 如請求項1之製備方法,其中該有機溶劑係選自由甲苯、二甲苯、二甲基甲醯胺(DMF)、二甲亞碸(DMSO)及其混合物所組成群組。The preparation method of claim 1, wherein the organic solvent is selected from the group consisting of toluene, xylene, dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and mixtures thereof. 如請求項2之製備方法,其中該有機溶劑為甲苯。The preparation method of claim 2, wherein the organic solvent is toluene. 如請求項1之製備方法,其中該銅催化劑係選自由CuI、Cu(OAc) 2、Cu、Cu 2O、CuO及其混合物所組成群組。 The preparation method of claim 1, wherein the copper catalyst is selected from the group consisting of CuI, Cu(OAc) 2 , Cu, Cu 2 O, CuO and mixtures thereof. 如請求項4之製備方法,其中該銅催化劑為CuI。The preparation method of claim 4, wherein the copper catalyst is CuI. 如請求項1之製備方法,其中該鹼係選自由碳酸鉀、碳酸銫、磷酸三鉀、三乙胺、三級丁醇鈉及其混合物所組成群組。The preparation method of claim 1, wherein the base is selected from the group consisting of potassium carbonate, cesium carbonate, tripotassium phosphate, triethylamine, sodium tributoxide and mixtures thereof. 如請求項1之製備方法,其中該鹼為碳酸鉀。The preparation method of claim 1, wherein the base is potassium carbonate. 如請求項1之製備方法,其中使用12至16 wt.%的該氨水NH 4OH或12至16 wt.%的該氯化銨(NH 4Cl)水溶液。 The preparation method of claim 1, wherein 12 to 16 wt.% of the aqueous ammonia (NH 4 OH) or 12 to 16 wt.% of the aqueous ammonium chloride (NH 4 Cl) solution is used. 如請求項1之製備方法,其中使用5至15 wt.%的該檸檬酸。The preparation method of claim 1, wherein 5 to 15 wt.% of citric acid is used. 如請求項1之製備方法,其進一步包含使用淨化水純化該化學式3之化合物。The preparation method of claim 1 further comprises purifying the compound of Chemical Formula 3 using purified water. 如請求項1至10中任一項之製備方法,其中X為Br,R1為CN,R2為氫,R3為異丙基,R4為氫,以及R5為乙氧基羰基(-C(O)OEt)。The preparation method of any one of claims 1 to 10, wherein X is Br, R1 is CN, R2 is hydrogen, R3 is isopropyl, R4 is hydrogen, and R5 is ethoxycarbonyl (-C(O)OEt).
TW113125897A 2023-07-10 2024-07-10 Method of preparing intermediates for synthesizing xanthine oxidase inhibitor TW202509022A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230088975 2023-07-10
KR10-2023-0088975 2023-07-10

Publications (1)

Publication Number Publication Date
TW202509022A true TW202509022A (en) 2025-03-01

Family

ID=94215782

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113125897A TW202509022A (en) 2023-07-10 2024-07-10 Method of preparing intermediates for synthesizing xanthine oxidase inhibitor

Country Status (3)

Country Link
KR (1) KR20250009377A (en)
TW (1) TW202509022A (en)
WO (1) WO2025014292A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI423962B (en) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
MA40281B1 (en) * 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Pyrazole compounds and their use as calcium channel blocking agents of type t
WO2022231261A1 (en) * 2021-04-27 2022-11-03 주식회사 엘지화학 Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
KR20220147531A (en) * 2021-04-27 2022-11-03 주식회사 엘지화학 Method of preparing xanthine oxidase inhibitor
WO2023277658A1 (en) * 2021-07-02 2023-01-05 주식회사 엘지화학 Method for preparing intermediate for synthesis of xanthine oxidase inhibitor

Also Published As

Publication number Publication date
WO2025014292A1 (en) 2025-01-16
KR20250009377A (en) 2025-01-17

Similar Documents

Publication Publication Date Title
JPH0770111A (en) Remedy against infectious disease caused by bacterial
EA012163B1 (en) Method for producing chiral 8-(3-amonopiperidin-1-yl)-xanthines
RU2480461C2 (en) Method of producing imatinib and intermediate compounds thereof
CN116354889B (en) Process for preparing benzimidazole derivatives
JPS61251650A (en) Method for producing (Z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride
AU2010272364B2 (en) Process for preparing levosimendan and intermediates for use in the process
TW202509022A (en) Method of preparing intermediates for synthesizing xanthine oxidase inhibitor
CN117561237A (en) Preparation method for intermediates used in the synthesis of xanthine oxidase inhibitors
CN114560862A (en) Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof
CN111848423A (en) Preparation method of tert-butyl 3-oxocyclobutylcarbamate
JP7532420B2 (en) Alternative method for preparing 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
KR20180123851A (en) Novel crystal form of lenalidomide and preparation of the same
CN115710213A (en) Preparation method of cis-chiral 3-fluoro-4-hydroxypiperidine and derivatives thereof
FR2618779A1 (en) NEW PROCESS FOR THE PREPARATION OF 1,2,4-TRIAZOL-3-ONES
EP3097082B1 (en) Processes for the synthesis of substituted urea compounds
CN116253715B (en) Preparation method of dabigatran etexilate intermediate
TWI822151B (en) Method for preparing xanthine oxidase inhibitor
KR100850558B1 (en) Efficient preparation of atorvastatin
US6333414B1 (en) Process for the synthesis of trisubstituted oxazoles
KR20230099857A (en) New process for preparing intermediate of urapidil
JPH0285237A (en) Production of methyl 3- aminocrotanate
JPH06100512A (en) Method for producing keto acid
JPH0446175A (en) Production of 5-hydroxy-3,4-methylenedioxybenzoic acid derivative
RU2213736C2 (en) Method for preparing 1-phenyl-4-methyl-4-hydroxymethylpyrazolidone-3
CN119707828A (en) Synthesis method of clemizole hydrochloride